Rifabutin Capsules, USP · PIN 09858390 · 150 mg · capsule
Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysNot paid by ODB 65 and over without Exceptional Access approval; the ministry's EAP drug list names this generic but not this DIN: confirm the product before an EAP request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchPrivate plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Rifabutin Capsules, USP · DIN 09858390
Manufacturer: Sterimax Inc.; listing date 2026-01-30
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Rifabutin Capsules, USP: Formulary list price $23.00 per unit (the source does not state the unit; exact figure $23.0000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858390)
Source record
DIN 09858390: Rifabutin Capsules, USP
Raw flags: sec3c=Y
Item: 081600021; group id 57; item number 0115; lccId None; manufacturer id STE
Source form: Cap; strength: 150mg
Recorded listing: Temporary benefit (shortage substitute)
Source prices (unrounded): $23.0000; ministry $23.0000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858390
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Therapeutic Notes (formulary)
For the prevention of Mycobacterium Avium Intracellular (MAI) in:
Patients with a CD4+ cell count less than 200/mm3 with an AIDS-defining diagnosis;
Patients with a CD4+ cell count less than 100/mm3 without an AIDS-defining diagnosis.
Shortage status: not checked (no credentials)